Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
10
11
12
13
14
15
16
19
11:00 AM - Charmalot 2025
20
21
22
23
24
25
26
27
29
1
2
3
4
5
Oracle Health and Life Sciences Summit 2025
2025-09-09 - 2025-09-11    
12:00 am
The largest gathering of Oracle Health (Formerly Cerner) users. It seems like Oracle Health has learned that it’s not enough for healthcare users to be [...]
MEDITECH Live 2025
2025-09-17 - 2025-09-19    
8:00 am - 4:30 pm
This is the MEDITECH user conference hosted at the amazing MEDITECH conference venue in Foxborough (just outside Boston). We’ll be covering all of the latest [...]
AI Leadership Strategy Summit
2025-09-18 - 2025-09-19    
12:00 am
AI is reshaping healthcare, but for executive leaders, adoption is only part of the equation. Success also requires making informed investments, establishing strong governance, and [...]
OMD Educates: Digital Health Conference 2025
2025-09-18 - 2025-09-19    
7:00 am - 5:00 pm
Why Attend? This is a one-of-a-kind opportunity to get tips from experts and colleagues on how to use your EMR and other innovative health technology [...]
Charmalot 2025
2025-09-19 - 2025-09-21    
11:00 am - 9:00 pm
This is the CharmHealth annual user conference which also includes the CharmHealth Innovation Challenge. We enjoyed the event last year and we’re excited to be [...]
Civitas 2025 Annual Conference
2025-09-28 - 2025-09-30    
8:00 am
Civitas Networks for Health 2025 Annual Conference: From Data to Doing Civitas’ Annual Conference convenes hundreds of industry leaders, decision-makers, and innovators to explore interoperability, [...]
TigerConnect + eVideon Unite Healthcare Communications
2025-09-30    
10:00 am
TigerConnect’s acquisition of eVideon represents a significant step forward in our mission to unify healthcare communications. By combining smart room technology with advanced clinical collaboration [...]
Pathology Visions 2025
2025-10-05 - 2025-10-07    
8:00 am - 5:00 pm
Elevate Patient Care: Discover the Power of DP & AI Pathology Visions unites 800+ digital pathology experts and peers tackling today's challenges and shaping tomorrow's [...]
Events on 2025-09-09
Events on 2025-09-17
MEDITECH Live 2025
17 Sep 25
MA
Events on 2025-09-18
OMD Educates: Digital Health Conference 2025
18 Sep 25
Toronto Congress Centre
Events on 2025-09-19
Charmalot 2025
19 Sep 25
CA
Events on 2025-09-28
Civitas 2025 Annual Conference
28 Sep 25
California
Events on 2025-10-05

Events

Latest News

Factors Predicting Poor Locoregional Control in Tongue Cancer

In patients with pT1-2N0 oral tongue squamous cell carcinoma undergoing partial glossectomy and elective neck dissection, inferior locoregional control (LRC) was associated with depth of invasion, lymphovascular space invasion, and positive glossectomy specimen margins. These retrospective findings, presented at the 2024 ASTRO Multidisciplinary Head and Neck Cancers Symposium, remained significant even in cases with final negative tumor bed margins.At a median follow-up of 45.6 months, the all-comer patient population exhibited 3-year locoregional control (LRC) and overall survival (OS) rates of 88.0% and 92.5%, respectively. Among patients with pT1 disease, these rates were 92.0% and 95.2%, while in those with pT2 disease, the rates were 85.0% and 90.5%.

However, during the multivariate analysis, individuals with positive glossectomy margins exhibited poorer locoregional control (HR, 6.66; 95% CI, 1.60-27.78; P = .009). Lymphovascular space invasion (HR, 6.90; 95% CI, 1.42-33.65; P = .02) and depth of invasion (HR, 1.31; 95% CI, 1.06-1.63; P = .01) were also correlated with diminished locoregional control.

The lead study author, Michael Modzelewski, MD, along with the co-investigators, stated in a poster presented at the meeting, “Patients with these risk factors may be considered for adjuvant radiotherapy to optimize disease control.”

Individuals with early-stage tongue squamous cell carcinoma typically do not undergo adjuvant radiation due to their low recurrence risk. After surgery, the status of the primary glossectomy specimen margin has been observed to have a stronger correlation with local recurrence than the status of additional tumor bed margins, as stated by the authors.

The investigators aimed to identify the pathological factors associated with locoregional recurrence in patients with early-stage tongue squamous cell carcinoma who underwent surgery alone. Additionally, they explored the impact of a positive glossectomy specimen margin on disease control concerning final negative tumor bed margins.

The research included 110 patients diagnosed with pT1-2N0 oral tongue squamous cancer, adhering to the American Joint Committee on Cancer (AJCC) 8th edition criteria. These individuals underwent partial glossectomy and elective dissection from 2015 to 2021, excluding adjuvant radiation. Pathology reports were examined for factors such as tumor size, depth of invasion, glossectomy specimen margin, final tumor bed margin status, and perineural or lymphovascular space invasion. Individuals with positive final margins or a history of head and neck radiation were excluded.

The Kaplan-Meier method was employed to estimate locoregional control (LRC) and overall survival (OS), with a Cox proportional hazards model identifying prognostic factors for LRC in multivariate analysis.

Concerning baseline characteristics, the median age was 52 years, with the majority being male (54.5%) and having pT2 stage disease (58.2%). There were 33 lymph nodes dissected on average, and the median tumor size measured 16 mm, with a depth of invasion reaching 5 mm.

The majority of patients did not exhibit perineural invasion (84.7%), while 3.6% had lymphovascular space invasion. Positive glossectomy specimen margins were observed in 8.2% of cases.

Further findings revealed that among patients with positive glossectomy specimen margins and those without, the 3-year locoregional control (LRC) rates were 66.7% and 89.5%, respectively. Similarly, the rates were 0.0% for individuals with lymphovascular space invasion and 89.4% for those without. Among the 8 patients experiencing regional failure, 5 had recurrence in the ipsilateral neck alone (62.5%), 2 in the bilateral neck (25.0%), and 1 with isolated contralateral neck recurrence (12.5%).